Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06840886 · ClinicalTrials.gov registry record · Phase 1
A Study of PHST001 in Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Pheast Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 155
- Enrollment target
- 10
- Study locations
NCT06840886: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Pheast Therapeutics.
NCT06840886 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Pheast Therapeutics. The registered enrollment target is 155 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (22% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06840886, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Pheast Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 155 participants
- Enrollment target
- 10
- Study locations
Study Summary
PHST001-101 is a multicenter, open-label, Phase 1 study of PHST001 in patients with advanced solid tumors. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced relapsed and/or refractory solid tumors. The study's primary object is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001.
Primary Outcome
Based on toxicities observed
Conditions Studied
Interventions
- DRUG PHST001
Study Locations (10)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- Stanford University School of Medicine - Palo Alto
Texas
- MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Connecticut
- Yale Cancer Center - New Haven
Illinois
- University of Chicago Medical Center - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
North Carolina
- Duke Cancer Institute - Durham
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2031-04 |
| Phase | Phase 1 |
What NCT06840886 shows while recruiting
NCT06840886 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which PHST001 is the first listed.
NCT06840886 lists 10 locations in 8 states (California, Texas, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06840886 about?
NCT06840886 is a clinical study titled "A Study of PHST001 in Advanced Solid Tumors". PHST001-101 is a multicenter, open-label, Phase 1 study of PHST001 in patients with advanced solid tumors. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced relapsed and/or refractory solid tumors. The study's primary object is to ev...
What is the current status of trial NCT06840886?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2025-03-31. Estimated completion is 2031-04.
What conditions does trial NCT06840886 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06840886?
The interventions under investigation include: PHST001 (DRUG).
Who is sponsoring clinical trial NCT06840886?
This trial is sponsored by Pheast Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06840886 being conducted?
This trial has 10 study locations across California, Connecticut, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06840886's enrollment target sits among peer trials
155 56th of 144 higher than 88 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI